Clinical Trial Update: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial of isatuximab with bortezomib, cyclophosphamide, and dexamethasone, followed by maintenance with isatuximab and lenalidomide in newly diagnosed mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Renal Impairment

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Isatuximab (isatuximab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Hellenic Society of Hematology | Conditions: Multiple Myeloma, Renal Impairment | Phase 2 | Status: UNKNOWN